SCHEMBL26313650

SCHEMBL26313650

CCCN(C(=O)c1cc(Cl)ccc1C#N)c1ccccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 4/20 0.43
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
TSHR P16473 1/20 0.40
CYP3A4 P08684 2/20 0.40
TP53 P04637 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
NOS2 P35228 2/20 0.37
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
CYP2D6 P10635 2/20 0.36
ESR1 P03372 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25411335 0.88 CYP3A4 (0.47) KMT2AMEN1CYP3A4MRGPRX4KDM4E
SCHEMBL26313653 0.86 TSHR (0.52) GPBAR1KMT2AMEN1TSHRCYP3A4
SCHEMBL25414906 0.84 TMEM97 (0.38) GPBAR1KMT2AMEN1TSHRMRGPRX4
SCHEMBL25414911 0.84 MRGPRX4 (0.37) GPBAR1KMT2AMEN1TSHRCYP3A4
SCHEMBL26313641 0.82 KMT2A (0.45) GPBAR1KMT2AMEN1TSHRCYP3A4
SCHEMBL26313781 0.81 IDO1 (0.40) GPBAR1KMT2AMEN1TSHRTP53
SCHEMBL30597297 0.81 IDO1 (0.40) GPBAR1KMT2AMEN1TSHRTP53
SCHEMBL26313667 0.76 TSHR (0.47) GPBAR1KMT2AMEN1TSHRCYP3A4
SCHEMBL26313663 0.74 TSHR (0.45) TSHRCYP3A4TP53KDM4EALDH1A1
SCHEMBL26313764 0.74 CYP3A4 (0.55) TSHRCYP3A4TP53MRGPRX4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286913-A1 INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF Gacter Inc. (US) 2023-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286913-A1 INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF NOS1, NOS3, NOS2 GPBAR1 1592/4885KMT2A 3286/4885MEN1 2794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.